GB9916882D0
(en)
*
|
1999-07-19 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Antitumor synergistic composition
|
WO2003086395A1
(en)
|
2002-04-12 |
2003-10-23 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
AU2003250701A1
(en)
|
2002-07-31 |
2004-02-16 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
ES2298563T3
(es)
|
2002-10-09 |
2008-05-16 |
Critical Outcome Technologies, Inc. |
Inhibidores de proteinas tirosina cinasas.
|
DE10354060A1
(de)
|
2003-11-19 |
2005-06-02 |
Merck Patent Gmbh |
Pyrrolderivate
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
CN100438913C
(zh)
*
|
2004-11-22 |
2008-12-03 |
山东蓝金生物工程有限公司 |
一种抗癌药物组合物
|
CN100350974C
(zh)
*
|
2005-02-03 |
2007-11-28 |
山东蓝金生物工程有限公司 |
一种抗癌药物组合物
|
CN100402091C
(zh)
*
|
2005-02-03 |
2008-07-16 |
山东蓝金生物工程有限公司 |
一种抗癌药物组合物
|
DE102005016634A1
(de)
|
2005-04-12 |
2006-10-19 |
Merck Patent Gmbh |
Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
|
JP5033119B2
(ja)
|
2005-04-25 |
2012-09-26 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
キナーゼ阻害剤としての新規アザ複素環化合物
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
DE102005061840A1
(de)
|
2005-12-23 |
2007-06-28 |
Merck Patent Gmbh |
Triazolderivate
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
DK2099442T3
(en)
|
2006-12-26 |
2015-02-16 |
Pharmacyclics Inc |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
EP2109608B1
(en)
|
2007-01-10 |
2011-03-23 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
DE102007008419A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
DE102007013856A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Substituierte Tetrahydropyrrolochinoline
|
DE102007013855A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Substituierte Tetrahydrochinoline
|
DE102007013854A1
(de)
|
2007-03-20 |
2008-09-25 |
Merck Patent Gmbh |
Tetrahydrochinoline
|
CN101754965B
(zh)
|
2007-05-21 |
2014-03-19 |
诺华股份有限公司 |
Csf-1r抑制剂、组合物及使用方法
|
DE102007028515A1
(de)
|
2007-06-21 |
2008-12-24 |
Merck Patent Gmbh |
6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
DE102007047737A1
(de)
|
2007-10-05 |
2009-04-30 |
Merck Patent Gmbh |
Piperidin- und Piperazinderivate
|
DE102007047735A1
(de)
|
2007-10-05 |
2009-04-09 |
Merck Patent Gmbh |
Thiazolderivate
|
DE102007047738A1
(de)
|
2007-10-05 |
2009-04-09 |
Merck Patent Gmbh |
Imidazolderivate
|
DE102007049451A1
(de)
|
2007-10-16 |
2009-04-23 |
Merck Patent Gmbh |
5-Cyano-thienopyridine
|
AU2008336249B2
(en)
|
2007-12-10 |
2015-01-29 |
The University Of Queensland |
Treatment and prophylaxis
|
EP2225226B1
(en)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Compounds and their use in a method for treatment of cancer
|
DE102008005493A1
(de)
|
2008-01-22 |
2009-07-23 |
Merck Patent Gmbh |
4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
|
DE102008017853A1
(de)
|
2008-04-09 |
2009-10-15 |
Merck Patent Gmbh |
Thienopyrimidine
|
US8466193B2
(en)
|
2008-04-15 |
2013-06-18 |
Pharmacyclics, Inc. |
Selective inhibitors of histone deacetylase
|
DE102008025751A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
|
DE102008027574A1
(de)
|
2008-06-10 |
2009-12-17 |
Merck Patent Gmbh |
Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
|
DE102008031517A1
(de)
|
2008-07-03 |
2010-01-07 |
Merck Patent Gmbh |
Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
|
CA2730890C
(en)
|
2008-07-17 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
DE102008059578A1
(de)
|
2008-11-28 |
2010-06-10 |
Merck Patent Gmbh |
Benzo-Naphtyridin Verbindungen
|
DE102009005193A1
(de)
|
2009-01-20 |
2010-07-22 |
Merck Patent Gmbh |
Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
US8329907B2
(en)
|
2009-04-02 |
2012-12-11 |
Merck Patent Gmbh |
Autotaxin inhibitors
|
EA201101399A1
(ru)
|
2009-04-02 |
2012-08-30 |
Мерк Патент Гмбх |
Гетероциклические соединения в качестве ингибиторов аутотаксина
|
MX2011010203A
(es)
|
2009-04-02 |
2011-10-14 |
Merck Patent Gmbh |
Derivados de piperidina y piperazina como inhibidores de autotaxina.
|
DE102009019962A1
(de)
|
2009-05-05 |
2010-11-11 |
Merck Patent Gmbh |
3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
DE102009033208A1
(de)
|
2009-07-15 |
2011-01-20 |
Merck Patent Gmbh |
Aminopyridinderivate
|
DE102009033392A1
(de)
|
2009-07-16 |
2011-01-20 |
Merck Patent Gmbh |
Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
|
JP2013502441A
(ja)
|
2009-08-26 |
2013-01-24 |
アルバータ・ヘルス・サービシーズ |
新規コルヒチン誘導体、方法、およびその使用
|
DE102009049211A1
(de)
|
2009-10-13 |
2011-04-28 |
Merck Patent Gmbh |
Sulfoxide
|
EP2488028B1
(en)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
WO2011054433A1
(en)
|
2009-11-07 |
2011-05-12 |
Merck Patent Gmbh |
Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
|
DE102009060174A1
(de)
|
2009-12-23 |
2011-06-30 |
Merck Patent GmbH, 64293 |
Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
|
DE102009060175A1
(de)
|
2009-12-23 |
2011-06-30 |
Merck Patent GmbH, 64293 |
Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
|
EP2519517B1
(en)
|
2009-12-29 |
2015-03-25 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
BR112012023021A2
(pt)
|
2010-03-16 |
2016-05-31 |
Dana Farber Cancer Inst Inc |
compostos de indazol e seus usos
|
AU2011232058B2
(en)
|
2010-03-26 |
2016-09-08 |
Merck Patent Gmbh |
Benzonaphthyridinamines as autotaxin inhibitors
|
EP3235818A3
(en)
|
2010-04-01 |
2018-03-14 |
Critical Outcome Technologies, Inc. |
Compounds for the treatment of hiv
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
ES2792799T3
(es)
|
2010-06-28 |
2020-11-12 |
Merck Patent Gmbh |
[1,8]naftiridinas 2,4-diaril-sustituidas como inhibidores de quinasas para su uso contra el cáncer
|
BR112012033658A2
(pt)
|
2010-07-05 |
2016-11-29 |
Merck Patent Gmbh |
derivados bipiridílicos úteis para o tratamento de doenças induzidas por quinases
|
CN103068980B
(zh)
|
2010-08-02 |
2017-04-05 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
|
KR102072631B1
(ko)
|
2010-08-17 |
2020-02-03 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US8859775B2
(en)
|
2010-09-02 |
2014-10-14 |
Merck Patent Gmbh |
Pyrazolopyridinone derivatives as LPA receptor antagonists
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
DE102010048374A1
(de)
|
2010-10-13 |
2012-04-19 |
Merck Patent Gmbh |
Pyrrolidinone als MetAP-2 Inhibitoren
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
DE102010049877A1
(de)
|
2010-11-01 |
2012-05-03 |
Merck Patent Gmbh |
7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
|
DE102010050558A1
(de)
|
2010-11-05 |
2012-05-10 |
Merck Patent Gmbh |
1H-Pyrrolo[2,3-b]pyridinderivate
|
DE102010053347A1
(de)
|
2010-12-03 |
2012-06-06 |
Merck Patent Gmbh |
3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
DE102011008352A1
(de)
|
2011-01-12 |
2012-07-12 |
Merck Patent Gmbh |
5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
|
DE102011009961A1
(de)
|
2011-02-01 |
2012-08-02 |
Merck Patent Gmbh |
7-Azaindolderivate
|
US9051318B2
(en)
|
2011-03-09 |
2015-06-09 |
Merck Patent Gmbh |
Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith
|
US20140046059A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Process for the preparation of morpholino sulfonyl indole derivatives
|
ES2699256T3
(es)
|
2011-05-23 |
2019-02-08 |
Merck Patent Gmbh |
Piridina y derivados de pirazina
|
EP3925962A1
(en)
|
2011-05-31 |
2021-12-22 |
Rakovina Therapeutics Inc. |
Tricyclic inhibitors of poly(adp-ribose) polymerase
|
DE102011105469A1
(de)
|
2011-06-24 |
2012-12-27 |
Merck Patent Gmbh |
7-Azaindolderivate
|
CN103717600B
(zh)
|
2011-08-10 |
2016-06-22 |
默克专利股份公司 |
吡啶并嘧啶衍生物
|
DE102011112978A1
(de)
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
Benzonitrilderivate
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
EP2822935B1
(en)
|
2011-11-17 |
2019-05-15 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
DE102011119127A1
(de)
|
2011-11-22 |
2013-05-23 |
Merck Patent Gmbh |
3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
|
SI2812337T1
(sl)
|
2012-02-09 |
2017-01-31 |
Merck Patent Gmbh |
Furo (3,2-b) in tieno (3,2-b) piridinski derivati kot zaviralci tbk1 in ikk
|
DE102012006884A1
(de)
|
2012-04-04 |
2013-10-10 |
Merck Patent Gmbh |
Cyclische Amide als MetAP-2 Inhibitoren
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
DE102012019369A1
(de)
|
2012-10-02 |
2014-04-03 |
Merck Patent Gmbh |
7-Azaindolderivat
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
ES2651347T3
(es)
|
2012-11-28 |
2018-01-25 |
Merck Sharp & Dohme Corp. |
Composiciones y métodos para el tratamiento del cáncer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
AU2014277262B2
(en)
|
2013-06-06 |
2019-10-03 |
Lead Discovery Center Gmbh |
A quinoline inhibitor of the macrophage stimulating 1 receptor MST1 R
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
CN107108679B
(zh)
|
2014-12-03 |
2020-10-23 |
糖模拟物有限公司 |
E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
EP3302710A4
(en)
|
2015-06-03 |
2019-02-20 |
The University of Queensland |
MOBILIZERS AND USE THEREOF
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2017151708A1
(en)
|
2016-03-02 |
2017-09-08 |
Glycomimetics, Inc. |
Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
|
US11066396B2
(en)
|
2016-06-23 |
2021-07-20 |
Merck Sharp & Dohme Corp. |
3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
|
US11433086B2
(en)
|
2016-08-08 |
2022-09-06 |
Glycomimetics, Inc. |
Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
JP7069136B2
(ja)
|
2016-10-07 |
2022-05-17 |
グリコミメティクス, インコーポレイテッド |
極めて強力な多量体e-セレクチンアンタゴニスト
|
JP7272956B2
(ja)
|
2017-03-15 |
2023-05-12 |
グリコミメティクス, インコーポレイテッド |
E-セレクチンアンタゴニストとしてのガラクトピラノシル-シクロヘキシル誘導体
|
US10851164B2
(en)
|
2017-04-13 |
2020-12-01 |
Aduro Biotech Holdings, Europe B.V. |
Anti-SIRPα antibodies
|
CN110996958B
(zh)
|
2017-08-16 |
2023-05-12 |
默克专利股份有限公司 |
包含5,10-亚甲基-(6r)-四氢叶酸以及二羧酸的稳定的冻干物
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
US11712446B2
(en)
|
2017-11-30 |
2023-08-01 |
Glycomimetics, Inc. |
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
|
CN111566117A
(zh)
|
2017-12-29 |
2020-08-21 |
糖模拟物有限公司 |
E-选择蛋白和半乳凝素-3的异双功能抑制剂
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
AU2019230013A1
(en)
|
2018-03-05 |
2020-09-10 |
Glycomimetics, Inc. |
Methods for treating acute myeloid leukemia and related conditions
|
US11874276B2
(en)
|
2018-04-05 |
2024-01-16 |
Dana-Farber Cancer Institute, Inc. |
STING levels as a biomarker for cancer immunotherapy
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US11845771B2
(en)
|
2018-12-27 |
2023-12-19 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
WO2021041532A1
(en)
|
2019-08-26 |
2021-03-04 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
WO2021126731A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|